BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP
867 results:

  • 1. Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort.
    Vanni I; Pastorino L; Andreotti V; Comandini D; Fornarini G; Grassi M; Puccini A; Tanda ET; Pastorino A; Martelli V; Mastracci L; Grillo F; Cabiddu F; Guadagno A; Coco S; Allavena E; Barbero F; Bruno W; Dalmasso B; Bellomo SE; Marchiò C; Spagnolo F; Sciallero S; Berrino E; Ghiorzo P
    J Transl Med; 2024 May; 22(1):462. PubMed ID: 38750555
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Genomic characterization and detection of potential therapeutic targets for peritoneal mesothelioma in current practice.
    van Kooten JP; Dietz MV; Dubbink HJ; Verhoef C; Aerts JGJV; Madsen EVE; von der Thüsen JH
    Clin Exp Med; 2024 Apr; 24(1):80. PubMed ID: 38642130
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. cancer trend and radiotherapy utilization at a tertiary academic hospital in Malaysia.
    Gan DEH; Bustam AZ
    J Cancer Res Ther; 2024 Jan; 20(1):358-362. PubMed ID: 38554346
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Combined detection of serum IL-6 and CEA contributes to the diagnosis of lung adenocarcinoma
    Pan J; Zhuang W; Xia Y; Huang Z; Zheng Y; Wang X; Huang Y
    PeerJ; 2024; 12():e17141. PubMed ID: 38529301
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Reliably making the primary diagnosis of mesothelioma utilizing serous fluid cytology specimens: an institutional experience.
    Jones TE; Geisler DL; Baskota SU; Ohori NP; Cuda J; Khader SN
    J Am Soc Cytopathol; 2024; 13(3):174-182. PubMed ID: 38514361
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Pleural mesothelioma (PMe): The evolving molecular knowledge of a rare and aggressive cancer.
    Rigon M; Mutti L; Campanella M
    Mol Oncol; 2024 Apr; 18(4):797-814. PubMed ID: 38459714
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Efficacy of neoadjuvant immunochemotherapy and survival surrogate analysis of neoadjuvant treatment in IB-IIIB lung squamous cell carcinoma.
    Liu J; Zhu L; Tang M; Huang X; Gu C; He C; Lv X; Hu J
    Sci Rep; 2024 Mar; 14(1):5523. PubMed ID: 38448498
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Case report of penile squamous cell carcinoma continuous treatment with BRCA2 mutation.
    Zhang Q; Li Y; Zhang Y; Deng Z; Ding Y
    World J Surg Oncol; 2024 Feb; 22(1):50. PubMed ID: 38336701
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. [A Case of Recurrent Breast cancer That Was brca1 Pathogenic Variant-Positive Successfully Treated with PARP Inhibitor].
    Aoyagi T; Namura M; Sakata H; Tamanuki T; Iwai M; Iwata K; Takahashi H; Matsuzaki H
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1462-1464. PubMed ID: 38303308
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Induced degradation of lineage-specific oncoproteins drives the therapeutic vulnerability of small cell lung cancer to PARP inhibitors.
    Kim C; Wang XD; Liu Z; Hao J; Wang S; Li P; Zi Z; Ding Q; Jang S; Kim J; Luo Y; Huffman KE; Pal Choudhuri S; Del Rio S; Cai L; Liang H; Drapkin BJ; Minna JD; Yu Y
    Sci Adv; 2024 Jan; 10(3):eadh2579. PubMed ID: 38241363
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
    Madorsky Rowdo FP; Xiao G; Khramtsova GF; Nguyen J; Martini R; Stonaker B; Boateng R; Oppong JK; Adjei EK; Awuah B; Kyei I; Aitpillah FS; Adinku MO; Ankomah K; Osei-Bonsu EB; Gyan KK; Altorki NK; Cheng E; Ginter PS; Hoda S; Newman L; Elemento O; Olopade OI; Davis MB; Martin ML; Bargonetti J
    Cancer Lett; 2024 Mar; 584():216608. PubMed ID: 38199587
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma.
    Al Balushi K; Al Hadhrami A; Balushi HA; Al Lawati A; Das S
    Curr Drug Targets; 2024; 25(3):149-157. PubMed ID: 38115619
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Value of adjuvant chemotherapy for patients with pT2N0M0 non-small cell lung cancer receiving radical resection.
    Chen S; Yang S; Zhao Y; Zhang Y; Huang Q; Wu H; Hu H; Sun Y; Zhang Y; Xiang J; Ye T; Chen H
    Thorac Cancer; 2024 Jan; 15(3):258-265. PubMed ID: 38098268
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Intraocular medulloepithelioma: an unusual and challenging entity in paediatric population.
    Imam U; Hameed M; Anis I; Bhutto I; Ahmed SH; Rizvi A; Ahmad Z
    J Pak Med Assoc; 2023 Dec; 73(12):2469-2472. PubMed ID: 38083935
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Non-coplanar lung SABR treatments delivered with a gantry-mounted x-ray tube.
    O'Connell J; Weil MD; Bazalova-Carter M
    Phys Med Biol; 2024 Jan; 69(2):. PubMed ID: 38035372
    [No Abstract]    [Full Text] [Related]  

  • 16. Disclosing Potential Therapeutic Targets Associated With Osimertinib Resistance in the Non-small Cell lung cancer Cell Line H1975.
    Tong X; Zhang R; Sun R; Yang W; Sun J; Chen J; Li F
    Anticancer Res; 2023 Dec; 43(12):5459-5474. PubMed ID: 38030186
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Rate of Pathogenic Germline Variants in Patients With lung cancer.
    Sorscher S; LoPiccolo J; Heald B; Chen E; Bristow SL; Michalski ST; Nielsen SM; Lacoste A; Keyder E; Lee H; Nussbaum RL; Martins R; Esplin ED
    JCO Precis Oncol; 2023 Sep; 7():e2300190. PubMed ID: 37992258
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Morphological characteristics of SETD2-mutated locally advanced clear cell renal cell carcinoma: Comparison with BAP1-mutated clear cell renal cell carcinoma.
    Takeda K; Bastacky S; Dhir R; Mohebnasab M; Quiroga-Garza GM
    Ann Diagn Pathol; 2024 Feb; 68():152223. PubMed ID: 37976977
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Comprehensive causes of death in uveal melanoma: mortality in 1530 consecutively diagnosed patients followed until death.
    Stålhammar G
    JNCI Cancer Spectr; 2023 Oct; 7(6):. PubMed ID: 37972025
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Enhancing Symptom Screening and Patient Education Among Patients with Metastatic lung cancer: a Qualitative Analysis.
    Safavi AH; Bryson E; Delibasic V; Tjong MC; Hallet J; Mahar A; Davis LE; Wright FC; Parmar A; Coburn NG; Louie AV
    J Cancer Educ; 2024 Feb; 39(1):86-95. PubMed ID: 37962792
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 44.